Barclays
FSTX

Barclays’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Barclays’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-226,433
Closed -$1.43M – 5516
2022
Q4 		$1.43M Hold
226,433
– – ﹤0.01% 2509
2022
Q3 		$1.16M Buy
226,433
+109,375
+93% +$687K ﹤0.01% 2129
2022
Q2 		$733K Buy
117,058
+41,868
+56% +$141K ﹤0.01% 2579
2022
Q1 		$267K Buy
+75,190
New +$278K ﹤0.01% 3258
2019
Q3 		– Sell
-4,539
Closed -$67K – 7281
2019
Q2 		$67K Buy
4,539
+3,560
+364% +$95.4K ﹤0.01% 5949
2019
Q1 		$41K Buy
979
+954
+3,816% +$40.2K ﹤0.01% 6020
2018
Q4 		$1K Sell
25
-1,289
-98% -$58K ﹤0.01% 6853
2018
Q3 		$63K Buy
1,314
+1,087
+479% +$54.4K ﹤0.01% 5925
2018
Q2 		$10K Sell
227
-148
-39% -$8.21K ﹤0.01% 6553
2018
Q1 		$23K Sell
375
-1,025
-73% -$54.1K ﹤0.01% 6379
2017
Q4 		$75K Buy
+1,400
New +$83.3K ﹤0.01% 5469

Barclays's FSTX Position: Q1 2023 in Review

Barclays sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 226,433 shares — an estimated $1.43M sold.

Barclays first reported a position in FSTX in Q4 2017 and held it in 11 quarters. The position peaked at $1.43M in Q4 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

  • Barclays reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Barclays sold 226,433 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.43M.
  • Barclays first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2017 and held it in 11 quarters.
  • Barclays's F-star Therapeutics, Inc. Common Stock position peaked at $1.43M in Q4 2022.
  • 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.